CN115181108A - 化合物及其制备方法、药物组合物和用途 - Google Patents

化合物及其制备方法、药物组合物和用途 Download PDF

Info

Publication number
CN115181108A
CN115181108A CN202210815568.3A CN202210815568A CN115181108A CN 115181108 A CN115181108 A CN 115181108A CN 202210815568 A CN202210815568 A CN 202210815568A CN 115181108 A CN115181108 A CN 115181108A
Authority
CN
China
Prior art keywords
compound
formula
ethyl
reacting
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210815568.3A
Other languages
English (en)
Chinese (zh)
Inventor
C.鲁施维内克基玛拉斯
H.费利普扎内蒂德阿泽维多
A.马斯加瑞罗
R.瓦坦纳贝达科斯塔
V.弗雷热托瑞斯卢索
E.曼诺西奥德素扎卢索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ache Laboratorios Farmaceuticos SA
Original Assignee
Ache Laboratorios Farmaceuticos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos SA filed Critical Ache Laboratorios Farmaceuticos SA
Publication of CN115181108A publication Critical patent/CN115181108A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202210815568.3A 2016-10-24 2017-10-23 化合物及其制备方法、药物组合物和用途 Pending CN115181108A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
BRBR1020160248140 2016-10-24
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
CN201780079647.XA CN110088092B (zh) 2016-10-24 2017-10-23 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780079647.XA Division CN110088092B (zh) 2016-10-24 2017-10-23 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法

Publications (1)

Publication Number Publication Date
CN115181108A true CN115181108A (zh) 2022-10-14

Family

ID=62023150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210815568.3A Pending CN115181108A (zh) 2016-10-24 2017-10-23 化合物及其制备方法、药物组合物和用途
CN201780079647.XA Active CN110088092B (zh) 2016-10-24 2017-10-23 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780079647.XA Active CN110088092B (zh) 2016-10-24 2017-10-23 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法

Country Status (20)

Country Link
US (2) US10781182B2 (enExample)
EP (2) EP3529234B1 (enExample)
JP (1) JP7194683B2 (enExample)
KR (1) KR102594251B1 (enExample)
CN (2) CN115181108A (enExample)
AR (1) AR109467A1 (enExample)
AU (1) AU2017351756B2 (enExample)
BR (1) BR102016024814A2 (enExample)
CL (1) CL2019001105A1 (enExample)
CO (1) CO2019004756A2 (enExample)
DK (1) DK3529234T3 (enExample)
EC (1) ECSP19032963A (enExample)
ES (2) ES2970546T3 (enExample)
FI (1) FI3529234T3 (enExample)
MX (1) MX392990B (enExample)
PE (2) PE20250558A1 (enExample)
PT (1) PT3529234T (enExample)
SG (2) SG11201903113TA (enExample)
UY (2) UY40644A (enExample)
WO (1) WO2018076090A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3640251T (lt) 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
JP7719796B2 (ja) 2020-04-24 2025-08-06 アストラゼネカ・アクチエボラーグ 医薬製剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276051A (en) * 1991-08-13 1994-01-04 Adir Et Compagnie Arylethylamine compounds
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US6376666B1 (en) * 1994-06-10 2002-04-23 Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk 2-mercaptobenzimidazole derivatives possessing pharmacological activity
WO2006134078A1 (en) * 2005-06-17 2006-12-21 Quimica Sintetica, S.A. Method for obtaining benzimidazole derivatives and intermediates thereof
US20070191447A1 (en) * 2004-02-23 2007-08-16 Toru Kodo Novel heterocyclic compound
US20090298811A1 (en) * 2006-09-12 2009-12-03 Pfizer Inc Benzimidazolone derivatives
US20100056515A1 (en) * 2006-10-25 2010-03-04 Kazuyoshi Aso Benzimidazole compounds
US20110245231A1 (en) * 2008-12-15 2011-10-06 Alla Chem, Llc Active substance and pharmaceutical composition for treating alcohol dependence, and a method for obtaining and the use of said active substance

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
ZA9711051B (en) 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
EP1189900B1 (en) 1999-06-30 2004-01-14 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276051A (en) * 1991-08-13 1994-01-04 Adir Et Compagnie Arylethylamine compounds
US6376666B1 (en) * 1994-06-10 2002-04-23 Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk 2-mercaptobenzimidazole derivatives possessing pharmacological activity
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US20070191447A1 (en) * 2004-02-23 2007-08-16 Toru Kodo Novel heterocyclic compound
WO2006134078A1 (en) * 2005-06-17 2006-12-21 Quimica Sintetica, S.A. Method for obtaining benzimidazole derivatives and intermediates thereof
US20090298811A1 (en) * 2006-09-12 2009-12-03 Pfizer Inc Benzimidazolone derivatives
US20100056515A1 (en) * 2006-10-25 2010-03-04 Kazuyoshi Aso Benzimidazole compounds
US20110245231A1 (en) * 2008-12-15 2011-10-06 Alla Chem, Llc Active substance and pharmaceutical composition for treating alcohol dependence, and a method for obtaining and the use of said active substance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIKHAIL V. VORONIN & ILYA A. KADNIKOV: "Contribution of Sigma-1 receptor to cytoprotective effect of afobazole", 《PHARMA RES PER》, vol. 4, no. 6, pages 1 - 8 *

Also Published As

Publication number Publication date
ES2970546T3 (es) 2024-05-29
EP3741760B1 (en) 2024-12-04
PE20191046A1 (es) 2019-08-06
AU2017351756B2 (en) 2022-01-27
SG11201903113TA (en) 2019-05-30
WO2018076090A1 (en) 2018-05-03
ES3013994T3 (en) 2025-04-16
JP7194683B2 (ja) 2022-12-22
BR112019008197A2 (pt) 2019-07-16
EP3529234B1 (en) 2023-11-29
KR20190066023A (ko) 2019-06-12
US11091445B2 (en) 2021-08-17
FI3529234T3 (fi) 2023-12-28
AR109467A1 (es) 2018-12-12
UY37334A (es) 2018-04-30
MX2019004782A (es) 2019-10-09
CL2019001105A1 (es) 2019-09-06
ECSP19032963A (es) 2019-05-31
PT3529234T (pt) 2024-02-01
CO2019004756A2 (es) 2019-05-21
UY40644A (es) 2024-02-29
DK3529234T3 (da) 2024-02-05
JP2019537624A (ja) 2019-12-26
US20190270711A1 (en) 2019-09-05
MX392990B (es) 2025-03-24
EP3529234A1 (en) 2019-08-28
CA3042040A1 (en) 2018-05-03
AU2017351756A1 (en) 2019-05-09
EP3741760A1 (en) 2020-11-25
CN110088092A (zh) 2019-08-02
PE20250558A1 (es) 2025-02-24
CN110088092B (zh) 2022-10-04
EP3529234A4 (en) 2020-03-11
SG10202009001TA (en) 2020-10-29
BR102016024814A2 (pt) 2018-05-08
US10781182B2 (en) 2020-09-22
KR102594251B1 (ko) 2023-10-25
US20200277265A1 (en) 2020-09-03
EP3741760C0 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
CN110088092B (zh) 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法
US8389544B2 (en) Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
JPH05501540A (ja) Ｐｃｐレセプター・リガンドおよびその用途
CN104395283A (zh) (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
WO2020062883A1 (zh) 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
JP2022511269A (ja) シャペロン介在性オートファジー調節剤として有用な化合物
JP2005538974A (ja) 中枢神経系の病気を治療するドーパミン−ｄ３リガンドとして使用するためのヘテロアレーンカルボキサミド
JPH10501239A (ja) メタ位置換のアリルアルキルアミン類ならびに治療および診断のためのその使用
EP4704833A2 (en) Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines
WO2009100120A2 (en) Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
HK40081925A (en) Compounds, and preparation process, pharmaceutical composition and use thereof
HK40011198B (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
HK40011198A (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
CA3042040C (en) 2-substituted benzimidazolyl compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
BR112019008197B1 (pt) Composto, processo de obtenção do composto, composição farmacêutica e uso do composto
KR102906581B1 (ko) 올레아난 신남아미드 유도체 및 이의 제조 방법과 용도
Badavath et al. Monoamine oxidase-A inhibitory activity of novel Curcumin analogues
WO2019029613A1 (zh) 一种氘代喹啉化合物及其制备和用途
Leopoldo et al. In Vitro and In Vivo Evaluation of N‐{2‐[4‐(3‐Cyanopyridin‐2‐yl) piperazin‐1‐yl] ethyl}‐3‐[11C] methoxybenzamide, a Positron Emission Tomography (PET) Radioligand for Dopamine D4 Receptors, in Rodents
Harel et al. New combination of pharmacophoric elements of potent σ1 ligands: Design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes
Fanini Synthesis and Chemical Optimization of New Melatonergic Ligands, including Multitarget Compounds
CN121568919A (zh) 不对称苯烷基胺
JP2025537145A (ja) Ｐａｒ２の低分子調節物質及びその使用
IL322951A (en) Hydroxyalkyl and methoxyalkyl-modified tryptamines
CN114426541A (zh) 氮杂芳基化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081925

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221014